Cerner facing class action lawsuit regarding overtime pay

Cerner could be facing a class action lawsuit over lack of overtime pay, according to multiple reports coming out of Kansas, City, Mo., the health IT vendor's home base.

Two former Cerner employees filed suit alleging Cerner miscalculated overtime pay for potentially thousands of workers, according to The Kansas City Star. Cerner employs nearly 17,000 people.

Cerner employees consistently worked more than 40 hours per week, but were not compensated with overtime pay as mandated under state and federal law, according to the lawsuit.

The plaintiffs are seeking to certify orders classifying the lack of overtime payment as willful, and unpaid back wages and damages for the affected employees, according to the report.

Cerner has taken action regarding this issue in the past, forcing employees in 2015 to choose between giving up the right to sue the company or merit-based pay raises. Employees who gave up the right to sue have legal complaints handled through internal arbitration.

This agreement will not affect this case because the lawsuit was filed before employees signed and agreed to give up the right to sue, according to a KCUR 89.3 report.

A similar overtime lawsuit against Cerner was initiated in 2007 but the case did not move forward as a class action lawsuit.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.